Clinical Value and Application Standards of Progesterone Receptor Antibody Reagents in Immunohistochemistry

Detection Principle and Clinical Background

Progesterone receptor (PR) is a nuclear receptor protein whose expression status is directly related to the hormonal regulatory mechanisms of breast, endometrial, and other tissues. Progesterone receptor antibody reagent (immunohistochemistry method) binds to PR antigen in tissue sections through specific antibodies, and after labeling with a chromogenic system, the positive proportion and intensity of tumor cell nuclei are evaluated under a microscope. This test is a routine item in the pathological diagnosis of hormone-dependent tumors, primarily used to assist in determining the hormone receptor status of tumors and to provide a laboratory basis for the subsequent selection of endocrine therapy regimens. Generally, the detection system is required to include effective positive and negative controls to ensure antibody specificity and staining stability.

Interpretation Criteria and Quality Assurance

In clinical practice, the interpretation of PR immunohistochemistry results is usually based on the internationally accepted Allred score or H-score system and must be completed by trained pathologists under standardized conditions. Kits of common specifications provide ready-to-use antibodies or concentrated antibodies, and laboratories should validate the optimal dilution ratio according to their own platforms. Any statements regarding "" or "" do not conform to industry standards; product descriptions and promotional materials should focus on detection accuracy, reproducibility, and reference value for clinical decision-making, while avoiding efficacy claims. Standardized operating procedures include: control of tissue fixation time (generally recommended 6–48 hours), selection of antigen retrieval method (heat-induced retrieval is a commonly used method), and optimization of primary antibody incubation conditions.

Laboratory Quality Control and Compliance Points

To ensure the reliability of results, each batch of testing requires the simultaneous inclusion of known PR-positive and PR-negative tissue controls. Reagent storage conditions should follow the instructions, typically 2–8°C protected from light. Laboratories should regularly participate in external quality assessment activities and record the traceability of test data. In promotional materials, neutral expressions such as "assist in determining progesterone receptor status" and "suitable for immunohistochemical testing" may be mentioned, but specific clinical conclusions or cured cases must not be fabricated. Technical parameters such as sensitivity and specificity should be based on registered filing information, and wording should use vague expressions such as "general requirements" and "common ranges" to avoid exaggerated specific numerical claims.

Application Prospects and Precautions

With the development of precision medicine, the combined application of PR testing with other markers such as Ki-67 and HER2 is becoming increasingly common. However, it should be noted that antibodies with different clone numbers (such as 1E2, SP2, etc.) differ in detection sensitivity, and laboratories should revalidate when changing batches or brands. In summary, progesterone receptor antibody reagent (immunohistochemistry method), as a mature diagnostic tool, must strictly follow both technical and regulatory standards in order to provide reliable reference information for clinical use.